Page 3 - Yong Qian News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: @Science China Press Cancer is the second leading cause of death in the world. The number of deaths and incidences is increasing each year. The metal-based anticancer drugs were used clinically worldwide, but suffer from poor selectivity, serious side effects and drug resistance. Tumor-targeting drug development is the basis for precise cancer treatment. Recently, Professor Hongke Liu of Nanjing Normal University, Professor Jing Zhao and Academician Zijian Guo of Nanjing University have made breakthrough achievements in anticancer drug development. They proposed a bio-orthogonally catalyzed lethality (BCL) strategy (Figure 1) and published their results in National Science Review (National Science Review, NSR). The BCL strategy uses tumors as manufacturing factories to generate a highly potential tumor-targeted drug Ru-rhein, which can selectively kill cancer cells and tumors in tumor-bearing mice, while no toxicity on normal cells. BCL strategy generates targeting dr

Jing zhaoYong qianQin taoHongke liuChenggen qianZijian guoJingwen dongYuanxin daiZhi suXuling xueNational natural science foundation of chinaNational science reviewProfessor hongke liuNanjing normal universityProfessor jing zhaoAcademician zijian guo